Citi Research reported that Sino Biopharm's (01177.HK) acquisition of Lixun Pharmaceutical will significantly expand its innovative product pipeline.
The note highlights Lixun's valuable assets, including: - LM-299 (PD-1/VEGF) licensed to Merck - LM-305 (GPRC5D ADC) licensed to AstraZeneca - LM-108 (CCR8 monoclonal antibody) - LM-302 (CLDN18.2 ADC)
This transaction represents a landmark in China's pharmaceutical sector as the industry's first major China-to-China acquisition. Citi maintains its "Buy" rating on Sino Biopharm with a HK$6.20 target price.
The research further notes significant progress in Sino Biopharm's innovative drug development: - TQC3721, the world's second-leading PDE3/4 inhibitor, initiated Phase III trials for COPD in June, demonstrating strong out-licensing potential - Pipeline assets including TQB6411 (EGFR/cMet ADC) and TQB3003 (fourth-generation EGFR TKI) have advanced to clinical stages
China's broader pharmaceutical and biotech industry continues to benefit from accelerating innovation and growing licensing trends.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。